Alnylam Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $1.66B | $966.4M | $812.7M | $866.4M | $820.0M | $496.6M | $547.2M | $420.1M |
| Accounts Receivable | $777.6M | $405.3M | $327.8M | $238.0M | $198.6M | $102.4M | $43.0M | $18.8M |
| Inventory | $82.7M | $78.5M | $89.1M | $129.0M | $86.4M | $75.2M | $56.3M | $24.1M |
| Total Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B |
| Property, Plant & Equipment | $513.1M | $502.8M | $526.1M | $523.5M | $502.0M | $465.0M | $425.2M | $320.7M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B |
| Liabilities | ||||||||
| Accounts Payable | $115.7M | $88.4M | $55.5M | $98.1M | $73.4M | $52.0M | $49.9M | $59.7M |
| Total Current Liabilities | $1.47B | $1.19B | $967.8M | $767.9M | $695.7M | $585.3M | $352.6M | $179.5M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956.4M | $272.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B |
| Total Stockholders' Equity | $789.2M | $67.1M | $-220.6M | $-158.2M | $588.2M | $1.02B | $1.44B | $1.30B |